Markers of Local and Systemic Inflammation in the Diarrhea Syndrome Associated with the Coronavirus Disease (COVID-19)
https://doi.org/10.35627/2219-5238/2023-31-10-62-70
Abstract
Introduction: Fecal calprotectin is known to be a biomarker of inflammatory bowel problems. An increase in its level has been also noted in COVID-19 patients, which is associated with the pathogenic effect of the virus on the intestinal epithelium involving components of nonspecific immunity.
Objective: To evaluate markers of local and systemic inflammation and their relationship in the diarrhea syndrome associated with the novel coronavirus disease (COVID-19).
Materials and methods: We have analyzed medical histories of 90 laboratory-verified SARS-CoV-2 patients aged 35 to 70 years and divided them into three equal groups of 30 cases each by the measured level of fecal calprotectin (Group 1: CPT > 200 μg/g, Group 2: CPT = 50 to 200 μg/g, and Group 3: CPT < 50 μg/g).
Results: In Group 1 patients with CPT > 200 μg/g, we observed a 1.5 times more frequent severe course of the coronavirus disease, pulmonary damage over 50 % (p < 0.05), fever and diarrhea that persisted up to 14.8 ± 0.5 and 8.7 ± 0.4 days, respectively (p < 0.05).
Conclusions: We established a direct relationship between markers of local and systemic inflammation. Clinical manifestations of COVID-19 correlated with the severity of intestinal inflammation. A positive correlation was found between fecal calprotectin levels and diarrhea syndrome duration. The landscape of opportunistic intestinal microbiota also correlated with the severity of the inflammatory process in the intestine.
About the Authors
A. U. Sabitov
Ural State Medical University
Russian Federation
Russian Federation
Dr. Sci. (Med.), Professor, Head of the Department of Infectious Diseases and Clinical Immunology, Ural State Medical University
3 Repin Street, Yekaterinburg, 620028
Yu. N. Moskaleva
Ural State Medical University; City Clinical Hospital No. 40
postgraduate student, Department of Infectious Diseases and Clinical Immunology, Ural State Medical University
3 Repin Street, Yekaterinburg, 620028
189 Volgogradskaya Street, Yekaterinburg, 620102
Y. B. Khamanova
Ural State Medical University; City Clinical Hospital No. 40
Dr. Sci. (Med.), Associate Professor, Department of Infectious Diseases and Clinical Immunology, Ural State Medical University; immunologist, City Clinical Hospital No. 40
3 Repin Street, Yekaterinburg, 620028
189 Volgogradskaya Street, Yekaterinburg, 620102
A. A. Sharova
Ural State Medical University
Cand. Sci. (Med.), Associate Professor, Department of Infectious Diseases and Clinical Immunology, Ural State Medical University
3 Repin Street, Yekaterinburg, 620028
A. V. Chashchina
Ural State Medical University
first-year resident, Ural State Medical University
3 Repin Street, Yekaterinburg, 620028
L. A. Schmalts
Ural State Medical University
first-year resident, Ural State Medical University
3 Repin Street, Yekaterinburg, 620028
References
1. Shafqat A, Shafqat S, Salameh SA, Kashir J, Alkattan K, Yaqinuddin A. Mechanistic insights into the immune pathophysiology of COVID-19; an in-depth review. Front Immunol. 2022;13:835104. doi: 10.3389/fimmu.2022.835104
2. Moroz EV, Tarasova ES, Agafonova SYu, Gracheva EN. Digestive system damage associated with SARS-CoV-2 infection. Meditsinskiy Vestnik GVKG im. N.N. Burdenko. 2021;(1(3)):26-36. (In Russ.)
3. Gu J, Han B, Wang J. COVID-19: Gastrointestinal manifestations and potential fecal–oral transmission. Gastroenterology. 2020;158(6):1518-1519. doi: 10.1053/j.gastro.2020.02.054
4. Samuelson DR, Welsh DA, Shellito JE. Regulation of lung immunity and host defense by the intestinal microbiota. Front Microbiol. 2015;6:1085. doi: 10.3389/fmicb.2015.01085
5. Novikova VP, Khavkin AI, Gorelov AV, Polunina AV. The lung–gut axis and COVID-19. Infektsionnye Bolezni. 2021;19(1):91-96. (In Russ.) doi: 10.20953/1729-9225- 2021-1-91-96
6. Smirnov VS, Totolyan AA. Innate immunity in coronavirus infection. Infektsiya i Immunitet. 2020;10(2):259–268. (In Russ.) doi: 10.15789/2220-7619-III-1440
7. Mago S, Vaziri H, Tadros M. The usefulness of fecal calprotectin in the era of the COVID-19 pandemic. Gas- troenterology. 2021;160(7):2623-2625. doi: 10.1053/j.gastro.2020.05.045
8. Giuffrè M, Vetrugno L, Di Bella S, Moretti R, Berretti D, Crocè LS. Calprotectin and SARS-CoV-2: A brief-report of the current literature. Healthcare (Basel). 2021;9(8):956. doi: 10.3390/healthcare9080956
9. Vakhlova IV, Fedotova GV, Boronina LG. Metabolic activity of gut microbiota in children during their first year of life which had undergone partial bowel resection. Rossiyskiy Pediatricheskiy Zhurnal. 2020;1(4):25-35. (In Russ.) doi: 10.15690/rpj.v1i4.2196
10. Ferreira C, Viana SD, Reis F. Gut microbiota dysbiosis – immune hyperresponse – inflammation triad in coro- navirus disease 2019 (COVID-19): Impact of pharmaco- logical and nutraceutical approaches. Microorganisms. 2020;8(10):1514. doi: 10.3390/microorganisms8101514
11. Magro F, Nuzzo A, Abreu C, et al. COVID-19 in gastro- enterology: Where are we now? Current evidence on the impact of COVID-19 in gastroenterology. United European Gastroenterol J. 2021;9(7):750-765. doi: 10.1002/ueg2.12115
12. Yeoh YK, Zuo T, Lui GC, et al. Gut microbiota com- position reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021;70(4):698-706. doi: 10.1136/gutjnl-2020-323020
13. Hanada S, Pirzadeh M, Carver KY, Deng JC. Respira- tory viral infection-induced microbiome alterations and secondary bacterial pneumonia. Front Immunol. 2018;9:2640. doi: 10.3389/fimmu.2018.02640
14. Xiao F, Sun J, Xu Y, et al. Infectious SARS-CoV-2 in feces of patient with severe COVID-19. Emerg Infect Dis. 2020;26(8):1920-1922. doi: 10.3201/eid2608.200681
15. Gaus OV, Belyakov DG. Modern views on the gut microbi- ota role in intestinal pathology. RMJ. 2021;29(4):10–16. (In Russ.)
16. Mazza S, Sorce A, Peyvandi F, Vecchi M, Caprioli F. A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis. Gut. 2020;69(6):1148- 1149. doi: 10.1136/gutjnl-2020-321183
17. Chan JFW, Kok KH, Zhu Z, et al. Genomic characteriza- tion of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221- 236. doi: 10.1080/22221751.2020.1719902
18. Dolgikh TI. [Damage to the gastrointestinal tract in COVID-19. Fecal transferrin and calprotectin as labo- ratory biomarkers of intestinal damage.] Spravochnik Zaveduyushchego KDL. 2021;(6):47-56. (In Russ.)
19. Golonka RM, Saha P, Yeoh BS, et al. Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease. Physiol Genomics. 2020;52(5):217- 221. doi: 10.1152/physiolgenomics.00033.2020
20. Ermolaeva LG, Belozerov SO, Dobrodeeva AA. Gut mi- crobiota as a predictor of COVID-19 severity. Zametki Uchenogo. 2020;(13):32-35. (In Russ.)
21. Effenberger M, Grabherr F, Mayr L, et al. Faecal calpro- tectin indicates intestinal inflammation in COVID-19. Gut. 2020;69(8):1543-1544. doi: 10.1136/gutjnl-2020-321388
22. Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533-535. doi: 10.1038/s41423-020-0402-2
23. Abaturov AE, Agafonova EA, Krivusha EL, Nikulina AA. Pathogenesis of COVID-19. Zdorov’e Rebenka. 2020;15(2):133-144. (In Russ.) doi: 10.22141/2224- 0551.15.2.2020.200598
24. Sánchez-Cerrillo I, Landete P, Aldave B, et al. COVID-19 severity associates with pulmonary redistribution of CD1c+ DCs and inflammatory transitional and nonclas- sical monocytes. J Clin Invest. 2020;130(12):6290-6300. doi: 10.1172/JCI140335
25. Vanderbeke L, Van Mol P, Van Herck Y, et al. Mo- nocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity. Nat Commun. 2021;12(1):4117. doi: 10.1038/s41467-021-24360-w
Supplementary files
Review
For citations:
Sabitov A.U., Moskaleva Yu.N., Khamanova Y.B., Sharova A.A., Chashchina A.V., Schmalts L.A. Markers of Local and Systemic Inflammation in the Diarrhea Syndrome Associated with the Coronavirus Disease (COVID-19). Public Health and Life Environment – PH&LE. 2023;31(10):62-70. (In Russ.) https://doi.org/10.35627/2219-5238/2023-31-10-62-70
Views:
313
.png)
Email this article 